MERZ PHARMACEUTICALS GMBH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1908-01-01

Employees: 101

Market Cap: -

Website: https://www.radiesse.de

Clinical Trials

Evaluate the Migration Potential of Xeomin® Compared to Two Other Botulinum Toxin Type A Products

Phase 1

Completed

Conditions: Healthy

First Posted Date: 2007-08-14

Last Posted Date: 2009-04-01

Lead Sponsor: Merz Pharmaceuticals GmbH

Target Recruit Count: 30

Registration Number: NCT00515944

Locations: 🇩🇪
Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany

Safety and Efficacy of NT 201 (IncobotulinumtoxinA [Xeomin]) in the Treatment of Glabellar Frown Lines

Phase 3

Completed

Conditions: Glabellar Lines

Interventions: Drug: IncobotulinumtoxinA (Xeomin) (20 units)

First Posted Date: 2007-08-07

Last Posted Date: 2021-04-02

Lead Sponsor: Merz Pharmaceuticals GmbH

Target Recruit Count: 801

Registration Number: NCT00512135

Locations: 🇺🇸
Coleman, Metairie, Louisiana, United States
🇺🇸
Tennessee Clinical Research Center, Nashville, Tennessee, United States
🇺🇸
About Skin Dermatology, Englewood, Colorado, United States

and more 22 locations

Blepharospasm Short Interval

Phase 2

Terminated

Conditions: Blepharospasm

Interventions: Drug: NT 201

First Posted Date: 2007-07-26

Last Posted Date: 2012-02-06

Lead Sponsor: Merz Pharmaceuticals GmbH

Target Recruit Count: 8

Registration Number: NCT00507637

Locations: 🇩🇪
Universitaets Augenklinik, Bonn, Germany

IncobotulinumtoxinA (Xeomin) for Upper Limb Spasticity

Phase 3

Completed

Conditions: Upper Limb Spasticity

Interventions: Drug: incobotulinumtoxinA (Xeomin, also known as "NT 201" or "Botulinum toxin type A (150 kD), free from complexing proteins")

First Posted Date: 2007-04-25

Last Posted Date: 2010-12-31

Lead Sponsor: Merz Pharmaceuticals GmbH

Target Recruit Count: 216

Registration Number: NCT00465738

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Post-stroke Spasticity of the Upper Limb

Phase 3

Completed

Conditions: Post-stroke Upper Limb Spasticity

Interventions: Drug: IncobotulinumtoxinA (Xeomin)
Drug: Placebo

First Posted Date: 2007-02-08

Last Posted Date: 2010-12-15

Lead Sponsor: Merz Pharmaceuticals GmbH

Target Recruit Count: 148

Registration Number: NCT00432666

Finding of Optimal Dose for NT 201 in the Treatment of Glabellar Frown Lines

Phase 2

Completed

Conditions: Glabellar Frown Lines

Interventions: Drug: Botulinum neurotoxin type A, free of complexing proteins
Drug: Placebo

First Posted Date: 2007-02-02

Last Posted Date: 2011-08-03

Lead Sponsor: Merz Pharmaceuticals GmbH

Target Recruit Count: 191

Registration Number: NCT00430586

Locations: 🇩🇪
Merz Pharmaceuticals GmbH, Frankfurt, Germany

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines

Phase 3

Completed

Conditions: Glabellar Frown Lines

Interventions: Drug: Placebo
Drug: IncobotulinumtoxinA (Xeomin) (20 Units)

First Posted Date: 2007-02-02

Last Posted Date: 2011-10-26

Lead Sponsor: Merz Pharmaceuticals GmbH

Target Recruit Count: 256

Registration Number: NCT00430963

Locations: 🇩🇪
Merz Pharmaceuticals GmbH, Frankfurt, Germany

Hyaluronic Acid Filler IMD1 Basic for Correction of Nasolabial Folds

Phase 4

Completed

Conditions: Nasolabial Folds

First Posted Date: 2007-01-31

Last Posted Date: 2008-02-07

Lead Sponsor: Merz Pharmaceuticals GmbH

Target Recruit Count: 114

Registration Number: NCT00429520

Locations: 🇩🇪
Merz Pharmaceuticals, Frankfurt, Germany

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm

Phase 3

Completed

Conditions: Blepharospasm

Interventions: Drug: Placebo
Drug: incobotulinumtoxinA (Xeomin)

First Posted Date: 2006-12-04

Last Posted Date: 2013-03-15

Lead Sponsor: Merz Pharmaceuticals GmbH

Target Recruit Count: 109

Registration Number: NCT00406367

Locations: 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇨🇦
David King, MD - Private Practice, Halifax, Nova Scotia, Canada

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Cervical Dystonia

Phase 3

Completed

Conditions: Cervical Dystonia

Interventions: Drug: incobotulinumtoxinA (Xeomin) (240 Units)
Drug: incobotulinumtoxinA (Xeomin) (120 Units)
Drug: Placebo

First Posted Date: 2006-12-04

Last Posted Date: 2013-07-19

Lead Sponsor: Merz Pharmaceuticals GmbH

Target Recruit Count: 233

Registration Number: NCT00407030

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy